Nachrichten zur Bristol-Myers Squibb Co Aktie

Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec…

Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft…

…

Kexing Biopharm: Shenzhen, China (ots/PRNewswire) - Am 28. Juli 2024 gab Kexing Biopharm die Genehmigung der Europäischen Kommission für Apexelsin®…

…

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…

…

…

The pharmaceutical company is faring far better than most investors were anticipating at this point.…

…

The pharmaceutical company is faring far better than most investors were anticipating at this point.…

BMY earnings call for the period ending June 30, 2024.…

…

Bristol-Myers Squibb stock gains after raising full-year guidance…

The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into…

Asking for a Trend Host Josh Lipton breaks down what to watch on Friday, July 26th. Personal Consumption Expenditures (PCE)…

The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033 and the Worldwide Musculoskeletal Market…

Bristol Myers Squibb Company, et al. v. Xavier Becerra, et al. Bristol Myers Squibb Company, et al. v. Xavier Becerra,…

Bristol-Myers Squibb faces challenges with patent expirations, but has long-term shareholder return potential. Read why BMY stock is a good investment.…

…

…

…

Bristol-Myers Squibb wird voraussichtlich am 26.07.2024 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 30.06.2024 – vorstellen.Die Schätzungen…

…

Does Bristol Myers have the potential to be a market-beating stock?…

Does Bristol Myers have the potential to be a market-beating stock?…

The Global Lenalidomide Drug Market Size was Valued at USD 12.34 Billion in 2023 and the Worldwide Lenalidomide Drug Market…

These two pharma stocks are beloved by income investors.…

…

OrganoClick has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClicks finance and economics department…

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

…

Bristol-Myers Squibb still elevated forward P/E indicates its unlikely to see an uptick anytime this year. Click here to read…

Evotec verkündet einen Fortschritt in der Partnerschaft mit Bristol Myers Squibb.…

Kulmbach (www.aktiencheck.de) - Evotec-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie der Evotec SE (ISIN: DE0005664809,…

Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec gibt Fortschritt in Neurologie-Partnerschaft mit…

…

…

…

…

…

BALTIMORE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Lawsuits have been filed alleging that a number of large…

…

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult…

…

…

The company is hoping to take on Bristol Myers Squibbs Camzyos, a treatment for obstructive HCM.…

The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake,…